Biosimilars Market Size and Overview

The global Biosimilars Market has emerged as one of the fastest-growing segments within the biopharmaceutical industry, driven by increasing patent expirations of blockbuster biologic drugs, rising healthcare expenditures, and growing demand for cost-effective treatment alternatives. Biosimilars are highly similar versions of approved biologic medicines that offer comparable safety, efficacy, and quality while helping reduce treatment costs for patients and healthcare systems. The market is witnessing strong adoption across therapeutic areas such as oncology, autoimmune diseases, diabetes, hematology, and inflammatory disorders.

The Biosimilars Market is experiencing substantial growth across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, supported by favorable regulatory frameworks and increasing physician confidence in biosimilar therapies.

Market Size

The global Biosimilars Market is valued at approximately USD 32 billion in 2026 and is projected to reach USD 92 billion by 2034, expanding at a compound annual growth rate (CAGR) of around 16% during the forecast period.

 

Access the full Report on Biosimilars Market  

 

Key Market Drivers

• Patent expiration of major biologic drugs creates significant biosimilar opportunities.
• Rising healthcare costs are increasing demand for affordable biologic alternatives.
• Favorable regulatory approvals are accelerating biosimilar market entry.
• Growing prevalence of cancer, autoimmune diseases, and chronic disorders boosts demand.
• Increasing physician and patient confidence supports wider biosimilar adoption.
• Advancements in biologics manufacturing improve product quality and scalability.
• Strategic partnerships and investments are expanding global biosimilar portfolios.

Demand Highlights

• Strong demand for cost-effective alternatives to branded biologics.
• Growing adoption in oncology, immunology, diabetes, and hematology treatments.
• Increasing utilization by hospitals, healthcare providers, and insurance systems.
• Rapid growth in emerging markets due to expanding healthcare access.
• Rising focus on reducing healthcare expenditure while maintaining treatment efficacy.

 

Market Segmentation

By Product Type (Leading Segments)

• Monoclonal Antibody Biosimilars – Largest market segment
• Insulin Biosimilars
• Recombinant Hormone Biosimilars
• Erythropoietin Biosimilars
• G-CSF Biosimilars
• Fusion Protein Biosimilars

By Therapeutic Area (Highest Demand)

• Oncology – Dominant segment
• Autoimmune & Inflammatory Diseases
• Diabetes
• Hematology
• Nephrology
• Endocrinology

By End User

• Hospitals – Leading end-user segment
• Specialty Clinics
• Ambulatory Surgical Centers
• Research Institutes

By Region

• Europe – Largest and most established biosimilars market
• North America
• Asia-Pacific (Fastest-growing region)
• Latin America
• Middle East & Africa

Top Companies in the Biosimilars Market

• Amgen
• Sandoz
• Pfizer
• Biocon Biologics
• Celltrion
• Samsung Bioepis
• Viatris
• Fresenius Kabi
• Teva Pharmaceutical Industries
• Dr. Reddy's Laboratories
• STADA Arzneimittel
• Organon
• Alvotech
• Coherus BioSciences
• Shanghai Henlius Biotech

1. Amgen

Amgen is a major global participant in the biosimilars market, leveraging decades of biologics manufacturing expertise to develop and commercialize biosimilar therapies. The company focuses on oncology, immunology, and supportive care biosimilars, offering alternatives to some of the world's most widely prescribed biologic medicines.

Amgen's biosimilar strategy centers on high-quality manufacturing, regulatory excellence, and broad geographic expansion. Through strong commercialization capabilities across North America, Europe, Asia-Pacific, and Latin America, the company continues to improve access to affordable biologic treatments while supporting healthcare system sustainability.

Key Highlights

• Extensive biosimilar portfolio
• Advanced biologics manufacturing expertise
• Strong oncology presence
• Global commercialization network
• Continuous biosimilar pipeline development

Category	Details
Founded	1980
Headquarters	Thousand Oaks, California, USA
Employees	Approx. 28,000
Revenue	Approx. USD 28 Billion
Industry	Biosimilars & Biopharmaceuticals
Key Products	Amjevita, Mvasi, Kanjinti, Riabni, Avsola

2. Sandoz

Sandoz is widely regarded as one of the pioneers of the global biosimilars industry. The company has built one of the largest biosimilar portfolios in the market, serving hospitals, healthcare providers, and patients across numerous therapeutic categories.

The company's biosimilar business is supported by advanced biotechnology platforms, large-scale manufacturing operations, and extensive regulatory expertise. Sandoz continues expanding its biosimilar pipeline through innovation, market penetration, and geographic diversification initiatives.

Key Highlights

• Pioneer in biosimilars commercialization
• Broad international market reach
• Strong regulatory track record
• Large biosimilar development pipeline
• Advanced manufacturing infrastructure

Category	Details
Founded	1886
Headquarters	Basel, Switzerland
Employees	Approx. 26,000
Revenue	Approx. USD 10 Billion
Industry	Biosimilars & Generic Medicines
Key Products	Hyrimoz, Zarxio, Ziextenzo, Tyruko, Omnitrope

3. Pfizer

Pfizer maintains a significant presence in the biosimilars market through the development and commercialization of biosimilar therapies targeting oncology, inflammatory diseases, and hematology applications. The company combines strong research capabilities with extensive global distribution networks.

Its biosimilar business benefits from large-scale manufacturing operations and well-established regulatory expertise. Pfizer continues investing in biosimilar expansion as healthcare systems increasingly seek cost-effective alternatives to branded biologics.

Key Highlights

• Strong global healthcare footprint
• Oncology-focused biosimilars portfolio
• Advanced biologics manufacturing
• Extensive regulatory capabilities
• Strategic market expansion initiatives

Category	Details
Founded	1849
Headquarters	New York, USA
Employees	Approx. 88,000
Revenue	Approx. USD 58 Billion
Industry	Biosimilars & Biopharmaceuticals
Key Products	Zirabev, Ruxience, Trazimera, Nivestym

4. Biocon Biologics

Biocon Biologics has emerged as one of the world's leading biosimilar companies, focusing on affordable biologic therapies for diabetes, oncology, and autoimmune disorders. The company has significantly expanded its international biosimilar footprint through acquisitions and strategic collaborations.

Its vertically integrated model spans development, manufacturing, regulatory approvals, and commercialization. Biocon Biologics continues strengthening healthcare accessibility by supplying high-quality biosimilars across developed and emerging markets.

Key Highlights

• Leading biosimilar company from India
• Strong insulin biosimilar expertise
• Global market expansion strategy
• Integrated biologics manufacturing
• Focus on affordability and access

Category	Details
Founded	2014
Headquarters	Bengaluru, India
Employees	Approx. 6,000
Revenue	Approx. USD 1 Billion
Industry	Biosimilars & Biologics
Key Products	Semglee, Hulio, Abevmy, Yesintek

5. Celltrion

Celltrion is a global biotechnology leader known for developing monoclonal antibody biosimilars. The company has achieved significant success in immunology and oncology biosimilars through extensive clinical research and manufacturing expertise.

Celltrion's integrated operations enable efficient development and commercialization of biosimilars across major global markets. The company continues expanding its product portfolio while investing in next-generation biologics technologies.

Key Highlights

• Strong monoclonal antibody capabilities
• Global biosimilar commercialization
• Large-scale biologics production
• Continuous product innovation
• Expanding international approvals

Category	Details
Founded	2002
Headquarters	Incheon, South Korea
Employees	Approx. 5,000
Revenue	Approx. USD 2 Billion
Industry	Biosimilars & Biotechnology
Key Products	Remsima, Yuflyma, Vegzelma, Herzuma

6. Samsung Bioepis

Samsung Bioepis specializes in the development and commercialization of biosimilars for autoimmune diseases, oncology, ophthalmology, and immunology applications. The company combines biotechnology innovation with extensive regulatory and manufacturing expertise.

Through strategic partnerships and international distribution agreements, Samsung Bioepis has established a strong presence across North America, Europe, and Asia-Pacific. Its growth strategy focuses on expanding access to affordable biologic therapies globally.

Key Highlights

• Advanced biosimilar development platform
• Strong global regulatory approvals
• Strategic commercialization partnerships
• Diverse therapeutic portfolio
• Continuous pipeline growth

Category	Details
Founded	2012
Headquarters	Incheon, South Korea
Employees	Approx. 2,500
Revenue	Approx. USD 1.5 Billion
Industry	Biosimilars & Biotechnology
Key Products	Hadlima, Byooviz, Ontruzant, Epysqli

7. Viatris

Viatris has established a significant biosimilars business through partnerships, commercialization agreements, and global distribution capabilities. The company focuses on improving patient access to biologic therapies through cost-effective biosimilar alternatives.

Its extensive healthcare infrastructure supports product availability across developed and emerging markets. Viatris continues investing in biosimilar expansion opportunities to strengthen its competitive position.

Key Highlights

• Extensive global reach
• Strong biosimilar commercialization expertise
• Broad healthcare distribution network
• Strategic biologics partnerships
• Focus on affordability

Category	Details
Founded	2020
Headquarters	Canonsburg, Pennsylvania, USA
Employees	Approx. 32,000
Revenue	Approx. USD 15 Billion
Industry	Biosimilars & Pharmaceuticals
Key Products	Semglee, Hulio, Abevmy, Ogivri

8. Fresenius Kabi

Fresenius Kabi has expanded its biosimilars portfolio through investments in oncology and immunology biologics. The company focuses on providing hospitals and healthcare providers with high-quality biosimilar medicines that improve treatment affordability.

The company continues enhancing manufacturing capabilities and global market access programs. Its biosimilars business supports healthcare systems seeking sustainable biologic treatment options.

Key Highlights

• Hospital-focused biosimilars strategy
• Oncology biosimilar expertise
• Global healthcare presence
• Regulatory compliance excellence
• Ongoing manufacturing investments

Category	Details
Founded	1912
Headquarters	Bad Homburg, Germany
Employees	Approx. 43,000
Revenue	Approx. USD 9 Billion
Industry	Biosimilars & Healthcare Products
Key Products	Idacio, Tyenne, Stimufend

9. Teva Pharmaceutical Industries

Teva participates in the biosimilars market through product development collaborations and commercialization initiatives focused on oncology and immunology therapies. The company leverages extensive pharmaceutical manufacturing expertise to support biosimilar growth.

Its biosimilar strategy emphasizes expanding patient access to advanced biologic treatments while maintaining quality and regulatory compliance standards across global markets.

Key Highlights

• Strong pharmaceutical manufacturing capabilities
• Global commercialization network
• Focus on biologic affordability
• Strategic biosimilar partnerships
• Expanding biosimilar opportunities

Category	Details
Founded	1901
Headquarters	Tel Aviv, Israel
Employees	Approx. 37,000
Revenue	Approx. USD 16 Billion
Industry	Biosimilars & Pharmaceuticals
Key Products	Truxima, Herzuma commercialization portfolio

10. Dr. Reddy's Laboratories

Dr. Reddy's Laboratories develops and commercializes biosimilars targeting oncology and autoimmune disease indications. The company has expanded its biosimilar footprint through biotechnology investments and strategic partnerships.

The company's strong presence in emerging and regulated markets supports wider access to biologic therapies. Continuous investment in biosimilar research strengthens its long-term growth strategy.

Key Highlights

• Growing biosimilar portfolio
• Biotechnology manufacturing expertise
• Strong emerging market presence
• Expanding regulatory approvals
• Affordable biologics focus

Category	Details
Founded	1984
Headquarters	Hyderabad, India
Employees	Approx. 26,000
Revenue	Approx. USD 3.5 Billion
Industry	Biosimilars & Pharmaceuticals
Key Products	Rituximab Biosimilar, Pegfilgrastim Biosimilar, Filgrastim Biosimilar

11. STADA Arzneimittel

STADA has strengthened its biosimilars business through strategic partnerships and commercialization agreements focused on oncology, immunology, and specialty biologics. The company has become a significant biosimilar supplier in Europe and other international markets.

STADA's growth strategy emphasizes portfolio expansion, healthcare affordability, and enhanced access to biologic medicines. The company continues expanding its biosimilar presence through collaborations and regulatory approvals.

Key Highlights

• Strong European biosimilars presence
• Partnership-driven growth strategy
• Expanding biologics portfolio
• Focus on healthcare accessibility
• International market expansion

Category	Details
Founded	1895
Headquarters	Bad Vilbel, Germany
Employees	Approx. 13,000
Revenue	Approx. USD 4 Billion
Industry	Biosimilars & Pharmaceuticals
Key Products	Hukyndra, Bevagen, Uzpruvo

12. Organon

Organon has entered the biosimilars market through strategic acquisitions and partnerships, focusing on expanding patient access to biologic therapies. The company emphasizes biosimilars as a key growth segment within its healthcare portfolio.

Its international commercialization capabilities support biosimilar distribution across multiple regions. Organon continues building a competitive biosimilars business through targeted investments and market expansion efforts.

Key Highlights

• Strategic biosimilar acquisitions
• Global commercialization capabilities
• Focus on biologic accessibility
• Partnership-based expansion
• Growing product portfolio

Category	Details
Founded	2021
Headquarters	Jersey City, New Jersey, USA
Employees	Approx. 10,000
Revenue	Approx. USD 6 Billion
Industry	Biosimilars & Healthcare
Key Products	Hadlima, Ontruzant, Renflexis

13. Alvotech

Alvotech is a dedicated biosimilars company focused exclusively on developing and manufacturing biosimilar medicines for global markets. Its business model centers on creating cost-effective alternatives to high-value biologic therapies.

The company operates advanced biologics manufacturing facilities and collaborates with international pharmaceutical partners to commercialize biosimilars worldwide. Alvotech continues expanding its pipeline targeting major biologic drug categories.

Key Highlights

• Pure-play biosimilars company
• Large biosimilar development pipeline
• Advanced manufacturing facilities
• Global commercialization partnerships
• Focus on affordability

Category	Details
Founded	2013
Headquarters	Reykjavik, Iceland
Employees	Approx. 1,000
Revenue	Approx. USD 400 Million
Industry	Biosimilars & Biotechnology
Key Products	AVT02, AVT04, AVT16, AVT23

14. Coherus BioSciences

Coherus BioSciences has established a strong position in the biosimilars market through commercialization of oncology and immunology biosimilars. The company focuses on increasing access to high-quality biologic alternatives in the United States and other key markets.

Its biosimilar strategy emphasizes efficient development pathways, commercialization excellence, and portfolio expansion. Coherus continues investing in biologics expertise and market growth initiatives.

Key Highlights

• Strong U.S. biosimilars presence
• Oncology-focused portfolio
• Commercialization expertise
• Growing market penetration
• Biosimilars innovation focus

Category	Details
Founded	2010
Headquarters	Redwood City, California, USA
Employees	Approx. 500
Revenue	Approx. USD 250 Million
Industry	Biosimilars & Biopharmaceuticals
Key Products	Udenyca, Yusimry

15. Shanghai Henlius Biotech

Shanghai Henlius Biotech is a rapidly growing biosimilars developer with a strong portfolio focused on oncology and autoimmune diseases. The company has achieved multiple regulatory approvals across Asia, Europe, Latin America, and other international regions.

Henlius continues investing in biologics innovation, manufacturing expansion, and global partnerships. Its biosimilars business supports broader patient access to advanced therapies while strengthening healthcare affordability worldwide.

Key Highlights

• Strong oncology biosimilar portfolio
• Expanding international approvals
• Advanced biologics manufacturing
• Growing global partnerships
• Continuous pipeline development

Category	Details
Founded	2010
Headquarters	Shanghai, China
Employees	Approx. 3,000
Revenue	Approx. USD 700 Million
Industry	Biosimilars & Biotechnology
Key Products	Hanlikang, Zercepac, Hanasai, Handayuan